Rice Hall James & Associates LLC Purchases New Position in Collegium Pharmaceutical, Inc. (COLL)

Rice Hall James & Associates LLC bought a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 56,464 shares of the specialty pharmaceutical company’s stock, valued at approximately $592,000. Rice Hall James & Associates LLC owned approximately 0.19% of Collegium Pharmaceutical at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. Credit Suisse AG grew its holdings in Collegium Pharmaceutical by 9.4% during the 1st quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after acquiring an additional 1,173 shares in the last quarter. Nationwide Fund Advisors grew its holdings in Collegium Pharmaceutical by 16.4% during the 1st quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after acquiring an additional 1,422 shares in the last quarter. American International Group Inc. grew its holdings in Collegium Pharmaceutical by 27.8% during the 1st quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after acquiring an additional 2,163 shares in the last quarter. Royal Bank of Canada grew its holdings in Collegium Pharmaceutical by 12.7% during the 2nd quarter. Royal Bank of Canada now owns 29,139 shares of the specialty pharmaceutical company’s stock worth $365,000 after acquiring an additional 3,285 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Collegium Pharmaceutical by 6.1% during the 1st quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock worth $656,000 after acquiring an additional 3,775 shares in the last quarter. Institutional investors own 83.06% of the company’s stock.

WARNING: “Rice Hall James & Associates LLC Purchases New Position in Collegium Pharmaceutical, Inc. (COLL)” was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2017/11/04/rice-hall-james-associates-llc-purchases-new-position-in-collegium-pharmaceutical-inc-coll.html.

Shares of Collegium Pharmaceutical, Inc. (NASDAQ COLL) opened at $9.82 on Friday.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.09. The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $4.07 million. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post -3 earnings per share for the current year.

Several research analysts have issued reports on the stock. Zacks Investment Research cut shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Piper Jaffray Companies set a $14.00 target price on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Tuesday, July 25th. Needham & Company LLC reiterated a “buy” rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Jefferies Group LLC reiterated a “buy” rating and set a $15.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Finally, BidaskClub cut shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $20.00.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

What are top analysts saying about Collegium Pharmaceutical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Collegium Pharmaceutical Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit